Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade
- PMID: 15289999
- DOI: 10.1007/s00213-004-1962-z
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade
Abstract
Rationale: The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors and as an antagonist at serotonin (5-HT)(2C) receptors.
Objectives: To determine whether, by virtue of its antagonist properties at 5-HT(2C) receptors, agomelatine elicits anxiolytic properties in rats.
Methods: Employing a combined neurochemical and behavioural approach, actions of agomelatine were compared to those of melatonin, the selective 5-HT(2C) receptor antagonist, SB243,213, and the benzodiazepine, clorazepate.
Results: In unfamiliar pairs of rats exposed to a novel environment, agomelatine enhanced the time devoted to active social interaction, an action mimicked by clorazepate and by SB243,213. In a Vogel conflict procedure, agomelatine likewise displayed dose-dependent anxiolytic activity with a maximal effect comparable to clorazepate, and SB243,213 was similarly active in this procedure. In a plus-maze procedure in which clorazepate significantly enhanced percentage entries into open arms, agomelatine revealed only modest activity and SB243,213 was inactive. Further, like SB243,213, and in contrast to clorazepate, agomelatine did not suppress ultrasonic vocalizations emitted by rats re-exposed to an environment associated with an aversive stimulus. Whereas clorazepate reduced dialysate levels of 5-HT and noradrenaline in hippocampus and frontal cortex of freely moving rats, agomelatine did not affect extracellular levels of 5-HT and elevated those of noradrenaline. SB243,213 acted similarly to agomelatine. Melatonin, which did not modify extracellular levels of 5-HT or noradrenaline, was ineffective in all models of anxiolytic activity. Furthermore, the selective melatonin antagonist, S22153, did not modify anxiolytic properties of agomelatine in either the social interaction or the Vogel Conflict tests.
Conclusions: In contrast to melatonin, and reflecting blockade of 5-HT(2C) receptors, agomelatine is active in several models of anxiolytic properties in rodents. The anxiolytic profile of agomelatine differs from that of benzodiazepines from which it may also be distinguished by its contrasting influence on corticolimbic monoaminergic pathways.
Similar articles
-
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9. Epub 2008 Jun 4. Psychopharmacology (Berl). 2008. PMID: 18523738
-
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. doi: 10.1124/jpet.103.051797. Epub 2003 May 15. J Pharmacol Exp Ther. 2003. PMID: 12750432
-
The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.Psychopharmacology (Berl). 2000 Sep;152(1):55-66. doi: 10.1007/s002130000449. Psychopharmacology (Berl). 2000. PMID: 11041316
-
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.Ther Adv Psychopharmacol. 2022 Jun 30;12:20451253221105128. doi: 10.1177/20451253221105128. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 35795687 Free PMC article. Review.
-
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. World J Biol Psychiatry. 2009. PMID: 19255935 Review.
Cited by
-
Agomelatine: a preliminary review of a new antidepressant.CNS Drugs. 2006;20(12):981-92. doi: 10.2165/00023210-200620120-00003. CNS Drugs. 2006. PMID: 17140278 Review.
-
Bipolar disorder: candidate drug targets.Mt Sinai J Med. 2008 May-Jun;75(3):226-47. doi: 10.1002/msj.20042. Mt Sinai J Med. 2008. PMID: 18704977 Free PMC article. Review.
-
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552. Pharmacol Rev. 2021. PMID: 33370241 Free PMC article. Review.
-
Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis.Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):423-433. doi: 10.9758/cpn.2020.18.3.423. Clin Psychopharmacol Neurosci. 2020. PMID: 32702221 Free PMC article.
-
The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders.Front Pharmacol. 2013 Jun 11;4:74. doi: 10.3389/fphar.2013.00074. eCollection 2013. Front Pharmacol. 2013. PMID: 23781201 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical